Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer
In this study, 48.6% of participants who received unusual or nonreportable clinical cfDNA-sequencing results had an occult cancer. Further study of DNA-sequencing patterns that are suggestive of occult cancer during prenatal screening is warranted. (Funded by the NIH Intramural Research Programs; ClinicalTrials.gov number, NCT04049604.).
Authors
- Jielu Lin
- Christina M. Annunziata (ORCID: https://orcid.org/0000-0003-2033-6532)
- Amy Turriff (ORCID: https://orcid.org/0000-0002-8065-7445)
- Padma Sheila Rajagopal (ORCID: https://orcid.org/0000-0002-0489-0819)
- Ian S. Goldlust (ORCID: https://orcid.org/0009-0003-2803-7219)
- Bernadette Redd (ORCID: https://orcid.org/0000-0001-9058-9485)
- Diana W. Bianchi (ORCID: https://orcid.org/0000-0001-9270-5267)
- Ashkan A. Malayeri (ORCID: https://orcid.org/0000-0002-4442-7343)
- Miroslava Pavelova (ORCID: https://orcid.org/0000-0001-5664-1067)
Institutions
- Leidos (United States) (US)
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Office of the Director (US)
- National Cancer Institute (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- Center for Cancer Research (US)
- National Institutes of Health Clinical Center (US)
- Leidos Biomedical Research Inc. (United States)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1056/nejmoa2401029
- Citations
- 30
- Primary Topic
- Prenatal Screening and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 33.28
Funders
- National Institutes of Health